Novarad Releases Web Version of Its Medical Image Sharing System, CyrptoChartTM

Novarad Corporation | June 02, 2022

Novarad Releases

The Industry leader in medical imaging technologies, Novorad, announced the release of a web-only version of CryptoChartTM, a cutting-edge medical imaging system that offers secure storage and transfer of digital health records through encrypted QR and web access codes. 

The Lite version of CryptoChartTM will be available at no extra cost, empowering patients and their providers with a seamless experience. Transparent and complete access to medical imaging technology. This will also eliminate accessibility concerns regardless of the geographical setting.

"One of the recurring frustrations by providers and patients alike is sharing information from different facilities while maintaining strict privacy. Being able to send large digital files like medical images quickly with a built-in viewer anywhere in the world helps simplify access, improve patient outcomes, and lower the cost of providing world-class care anywhere."

David GrandPre, Sr. Director of Product, Novarad

CryptoChartTM Lite instantly addresses the challenge of isolated systems and delivers a streamlined access to medical reports and imaging without the use of portals or login information. The information, URL, and passwords are embedded into an ultra-secure, optically readable, and shareable QR code. 

"The CryptoChart Lite service is exactly the prescription needed for healthcare professionals frustrated by the barriers of accessing medical images. It's like a medical Dropbox. Technology should make it easier to provide patient care, not get in our way. The Lite version allows facilities globally to try out the CryptoChart platform. We've made it easy with no sign-up required. Just drag and drop the file." Dr. Wendell Gibby, Founder and CEO, Novarad


In 2020 the world changed as we know it. The COVID-19 pandemic brought into sharp focus the vulnerabilities that exist in many healthcare systems. Healthcare providers had to quickly adapt their service delivery models, consider future possible scenarios, and continue to innovate.


In 2020 the world changed as we know it. The COVID-19 pandemic brought into sharp focus the vulnerabilities that exist in many healthcare systems. Healthcare providers had to quickly adapt their service delivery models, consider future possible scenarios, and continue to innovate.

Related News


Laborie Launches alpHaONE, an Innovative GERD Diagnostic System

prnewswire | April 04, 2023

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. announced the launch of the alpHaONE system that is specifically designed to diagnose gastroesophageal reflux disease and offers up to 96 hours of monitoring data. GERD is a chronic medical condition caused by the flow of contents from the stomach upwards into the esophagus resulting in both symptoms and complications. It is estimated that 20% of the US population suffers from GERD with the most common symptoms being heartburn and regurgitation1. With an increasing number of options for GERD diagnosis, patients and healthcare providers face a challenge in choosing the best solution for a clear diagnosis. alpHaONE offers a unique solution with its ergonomic and compact design, enlarged and easy-to-press buttons, and fail-safe capsule delivery system that protects the patient's esophagus. "alpHaONE is a patient-centric system that allows for comfortable monitoring and accurate, reliable data, fulfilling the needs of both patients and healthcare providers to diagnosis GERD," said Rhett Klein, Vice President of Sales and Marketing for Laborie's GI Business Unit. "Our primary objective has always been to provide solutions that elevate patient outcomes and enhance their overall experience and we look forward to launching this product." The comprehensive software application incorporated in the alpHaONE system consists of a Virtual Instruction Program, which allows for effortless navigation. In addition, user-customizable symptom buttons and automatic pH data analysis ensure a seamless user experience. Laborie will showcase alpHaONE at the Digestive Disease Week (DDW) event in Chicago, Illinois on May 6-9, 2023. About Laborie Medical Technologies Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health headquartered in Portsmouth, New Hampshire. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program.

Read More


AAFC Launches EASE® Healthcare Program in Ghana With FOCOS Orthopedic Hospital

businesswire | May 15, 2023

EASE® Ghana Limited, a subsidiary of African Asset Finance Company that provides state-of-the-art diagnostic equipment “as-a-service” to healthcare organizations, announces the signing of its first customer. The contract, which marks the launch of the EASE® Healthcare program in Ghana, will see the installation of a Siemens CT scanner in the Accra facility of FOCOS Orthopedic Hospital. “We are thrilled to announce this deal to bring a new, best-in-class CT scanner to one of Ghana’s leading healthcare providers,” said Kanyinsola Oyeyinka, AAFC’s VP Healthcare, Africa, responsible for AAFC’s EASE® Healthcare program across the continent. “The EASE® Healthcare program will support medical organisations across Africa in delivering the highest possible standard of health provision to their patients, and we are pleased to count FOCOS Hospital as one of our first customers.” Imraan Soomra, Chief Operations Officer of AAFC, added: “The Healthcare program is a significant element in our wider EASE® initiative, enabling customers to utilise best-in-class equipment they would otherwise be unable to access, benefiting organizations and their users.” In recent years, FOCOS Orthopedic Hospital has undergone a period of significant growth in clinic attendance. Between 2020 and 2022, the number of patients rose 60% year-on-year to over 11,000 – a figure that continues to rise. Through EASE® Ghana’s pay-per-scan service, the hospital will now be able to meet this increasing demand without facing exorbitant up-front costs – instead meeting the capital expense of its new Siemens CT scanner through cashflows generated in the use of the equipment itself. “Our pay-per-use model ensures that healthcare providers like FOCOS are able to access the highest quality equipment, whilst also benefiting from maintenance provision, operator training and ongoing support,” said Anita Appiah, EASE® Ghana's Business Development Manager. Dr Wulff, CEO of FOCOS Hospital commented: “With EASE, we're able to access first-rate diagnostic equipment for the hospital. This new scanner will add to our market-leading healthcare provision, enabling us to deliver an even higher quality of service to an even greater number of patients.” Dr Bernt Bieber, Senior Vice President, Siemens Healthineers comments: “The EASE program aligns with our purpose of making healthcare available to everyone, no matter where they live, and could meaningfully change the way healthcare is administered and accessed in the growing African market. We are excited to be part of it!" EASE® Ghana will upgrade FOCOS Hospital’s existing, non-functioning CT scanner with a new and upgraded CT from Siemens Healthineers (Somatom Go. Up CT 64 slice model). This new scanner will allow the hospital to significantly increase its daily exam volumes, boosting its ability to meet the needs of its patients without technical constraints on how many patients can be examined on a daily basis. About EASE® EASE® is an AAFC program that provides access to high-quality equipment – including maintenance, training and support – to businesses and organizations across Africa, allowing them to pay for the use of the equipment with the cashflows the equipment itself helps to generate.

Read More


Masimo Announces Major Expansion of the HEOS® Platform

Businesswire | May 25, 2023

Masimo announced the global expansion of the HEOS platform, enabling an always-on connection to the Masimo Health secure cloud for four million devices and empowering consumers with an enhanced health tracking experience. This software upgrade allows Masimo’s cutting-edge devices and secure cloud solution to seamlessly integrate with HEOS-enabled sound bars, wireless speakers, amplifiers, and receivers from Denon, Marantz, and Definitive Technology worldwide – including the U.S., Canada, United Kingdom, Japan, and Australia, with more countries going live later this year. “We are excited to expand the footprint and capabilities of our HEOS platform with our wearables and provide our customers with health tracking truly integrated with their favorite audio solutions,” said Joe Kiani, Founder and CEO of Masimo. “Now, four million devices around the world can help improve the lives of our customers by combining the joy of high-quality audio with the convenience of continuous and accurate health and wellness tracking from the comfort of their own homes.” Masimo’s groundbreaking HEOS ecosystem platform, combined with Masimo's latest wearable health and wellness devices – such as the Masimo W1™ advanced health tracking watch, and soon the Stork™ baby monitor and Radius Tº™ continuous thermometer, select Masimo medical devices, and more – will allow users to keep track of their health and wellness, as well as share their data with loved ones and clinicians, paving the way for the next chapter in telehealth innovation and cohesive care. This latest ecosystem innovation not only wirelessly relays health data to the HEOS-enabled home device and Masimo’s secure Health cloud for storage, analysis, reporting, and transfer, but now offers a revolutionary way to connect and interact with health technologies from the company that, among many other medical breakthroughs, invented Masimo SET® – the primary pulse oximetry at 9 of the top 10 U.S. hospitals. “The HEOS platform embodies the true essence of luxury in the modern era, where health and wellness take center stage. These new capabilities redefine what it means to live a life centered around wellness, and empower individuals to embrace self-care as an essential part of that life, transforming their lives with innovative technology and personalized insights,” Mr. Kiani continued. “We believe the health hub feature will not only differentiate Masimo audio products in the eyes of consumers worldwide, but also bring forth the next level of health and wellness by allowing connected care as consumers move around tetherless and even smartphone-less.” Whether it’s enjoying music in the living room, kitchen, or bedroom, experiencing movie night with the family, or getting a workout in their home gyms, users all over the globe can effortlessly connect and track and record key health data from Masimo wearable monitoring devices, including pulse rate, oxygen saturation, respiration rate, hydration index, and more, using their HEOS-enabled devices. Customers will be able to access this new functionality through a cloud software update to their existing devices, which ensures a hassle-free transition to the enhanced music and health hub platform. Some technologies and devices described may not be available or approved in every market. About Masimo Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.5-8

Read More